Powder: -20°C for 3 years | In solvent: -80°C for 1 year
UC-1V150 is a distinct TLR7 agonist, which activates cellular immune responses and exhibits anti-tumor effects. It also serves as a precursor for the synthesis of ISAC molecules, known as immune-stimulating antibody conjugates [1] [2].
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
25 mg | ¥ 10,600 | 6-8周 | ||
50 mg | ¥ 13,800 | 6-8周 | ||
100 mg | ¥ 17,500 | 6-8周 |
产品描述 | UC-1V150 is a distinct TLR7 agonist, which activates cellular immune responses and exhibits anti-tumor effects. It also serves as a precursor for the synthesis of ISAC molecules, known as immune-stimulating antibody conjugates [1] [2]. |
体外活性 | UC-1V150 (0.01-10 μM, 24 hour) can stimulate the release of IL-6 and IL-2 cytokines effectively in bone-marrow-derived macrophages [1]. UC-1V150 (1 μg/mL, 48 hours) can increase the expression of FcγRIIA and FcγRIII while inducing an approximately 1.5-fold increase in macrophage phagocytosis index of target cells in hman monocyte-derived macrophages (hMDM) [2]. |
体内活性 | UC-1V150 (intravenous injection, 0.38-38 nM, once, 2 hours) effectively induces release of serum cytokines within a certain concentration range in female C57BL/6 mice (5-6 weeks of age) [1]. Animal Model: Female C57BL/6 mice (5–6 weeks of age) [1] Dosage: 0.38-38 nM Administration: Intravenous injection; once; 2 hours Result: Induced serum cytokine IL-6 levels about 0.1 ng/mL and IL-2 levels about 1.5 ng/mL at the concentration of 38 nM. |
分子量 | 343.34 |
分子式 | C16H17N5O4 |
CAS No. | 927822-45-5 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
UC-1V150 927822-45-5 Inhibitor inhibitor inhibit